ADVIL ALLERGY AND CONGESTION RELIEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADVIL ALLERGY AND CONGESTION RELIEF (ADVIL ALLERGY AND CONGESTION RELIEF).
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.
| Metabolism | Ibuprofen is primarily metabolized by cytochrome P450 (CYP) enzymes, mainly CYP2C9, to inactive metabolites (hydroxyibuprofen and carboxyibuprofen). Pseudoephedrine is partially metabolized in the liver by N-demethylation to an inactive metabolite. |
| Excretion | Renal excretion of unchanged drug and metabolites; approximately 1% excreted unchanged (pseudoephedrine) and 15% (ibuprofen). Biliary/fecal elimination accounts for <5%. |
| Half-life | Ibuprofen: 2-4 hours; pseudoephedrine: 5-8 hours. Shorter half-life requires frequent dosing for sustained relief. |
| Protein binding | Ibuprofen: 99% bound to albumin; pseudoephedrine: negligible protein binding. |
| Volume of Distribution | Ibuprofen: 0.1-0.2 L/kg; pseudoephedrine: 2.5-3 L/kg. |
| Bioavailability | Oral: ibuprofen 80-100%; pseudoephedrine 100%. |
| Onset of Action | Oral: ibuprofen onset 30-60 minutes; pseudoephedrine onset 15-30 minutes. |
| Duration of Action | Ibuprofen: 4-6 hours; pseudoephedrine: 4-6 hours. Duration may be shorter with immediate-release formulations. |
| Molecular Weight | Ibuprofen: 206.29 Da; Pseudoephedrine: 165.23 Da |
Ibuprofen 200 mg and pseudoephedrine HCl 30 mg per tablet. Usual adult dose: 1-2 tablets orally every 4-6 hours as needed, not to exceed 6 tablets in 24 hours.
| Dosage form | TABLET |
| Renal impairment | For pseudoephedrine: CrCl <30 mL/min, reduce dose by 50% or administer every 12 hours. For ibuprofen: avoid use if CrCl <30 mL/min; if CrCl 30-59 mL/min, use lowest effective dose and monitor renal function. |
| Liver impairment | For ibuprofen: Child-Pugh class A and B: no adjustment necessary; Child-Pugh class C: avoid use. For pseudoephedrine: use with caution in severe hepatic impairment; no specific dose adjustment recommended, but monitor for adverse effects. |
| Pediatric use | Not indicated for children under 12 years of age. For children 12 years and older: same as adult dose (1-2 tablets every 4-6 hours, max 6 tablets per day). Weight-based: not routinely used; safety and efficacy not established for <25 kg. |
| Geriatric use | For ibuprofen: use lowest effective dose for shortest duration; monitor renal function and GI bleeding risk. For pseudoephedrine: initiate at lower doses (e.g., one tablet every 6 hours) due to increased sensitivity and risk of hypertension, urinary retention, and CNS effects. |
| 1st trimester | Avoid unless benefit outweighs risk; contains ibuprofen (NSAID) associated with increased risk of miscarriage and congenital malformations (e.g., cardiac defects, gastroschisis) — if used, limit to lowest effective dose and shortest duration; pseudoephedrine use is associated with small risk of gastroschisis and hemifacial microsomia. |
| 2nd trimester | Avoid; ibuprofen may cause oligohydramnios and premature ductus arteriosus constriction; use only if absolutely necessary and for minimal duration. |
| 3rd trimester | Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment with ibuprofen; pseudoephedrine may cause uterine artery vasoconstriction. |
Clinical note
Comprehensive clinical and safety monograph for ADVIL ALLERGY AND CONGESTION RELIEF (ADVIL ALLERGY AND CONGESTION RELIEF).
| Placental transfer | Both ibuprofen and pseudoephedrine cross the placenta; ibuprofen undergoes passive diffusion with fetal concentrations about 10-50% of maternal; pseudoephedrine readily crosses, with fetal levels ~70% of maternal. |
■ FDA Black Box Warning
Cardiovascular risk: NSAIDs may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for perioperative pain in coronary artery bypass graft (CABG) surgery. Gastrointestinal risk: NSAIDs increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and those with prior peptic ulcer disease and/or GI bleeding are at greater risk.
| Serious Effects |
Pregnancy (third trimester)History of allergic reaction to ibuprofen, aspirin, or other NSAIDsActive peptic ulcer disease or GI bleedingSevere hypertension or coronary artery disease (due to pseudoephedrine)Concomitant use of MAO inhibitors or within 14 days of MAOI therapy
| Precautions | Cardiovascular effects: may increase risk of heart attack or stroke; use lowest effective dose for shortest duration. Gastrointestinal effects: may cause GI ulceration, bleeding, perforation. Renal effects: avoid in advanced renal disease; monitor renal function. Hepatic effects: may cause liver enzyme elevation; discontinue if liver disease develops. Anaphylactic reactions: may occur in patients with or without prior NSAID sensitivity. Asthma: may cause bronchospasm. Hypertension: may worsen hypertension. Avoid in late pregnancy due to risk of premature closure of ductus arteriosus. Pseudoephedrine: may cause nervousness, dizziness, insomnia, hypertension, arrhythmias; use with caution in patients with cardiovascular disease, diabetes, glaucoma, prostatic hypertrophy, hyperthyroidism. Avoid in severe hypertension or coronary artery disease. |
Loading safety data…
| Breastfeeding |
| Ibuprofen enters breast milk in trace amounts (0.0008% of maternal dose) and is generally considered compatible with breastfeeding; pseudoephedrine is excreted into breast milk and may cause irritability and decreased milk production (dose-dependent); use lowest effective dose for shortest duration and monitor infant for sedation or irritability. |
| Lactation Rating | L2 (Safer, for ibuprofen component; pseudoephedrine rated L3 – moderately safe, but caution advised) |
| Teratogenic Risk | First trimester: Possible increased risk of cardiovascular malformations and gastroschisis with NSAID use. Second trimester: No specific malformation risk reported, but avoid prolonged use due to potential oligohydramnios. Third trimester: NSAIDs (including ibuprofen) are contraindicated due to risk of premature ductus arteriosus closure and oligohydramnios. Pseudoephedrine: Limited data; possible association with gastroschisis if used in first trimester; avoid due to vasoconstrictive effects. |
| Fetal Monitoring | Monitor for fetal ductus arteriosus constriction and oligohydramnios with prolonged ibuprofen use in third trimester. Monitor maternal blood pressure, heart rate, and renal function due to pseudoephedrine. Assess fetal growth and amniotic fluid volume via ultrasound if used beyond 30 weeks gestation. |
| Fertility Effects | Ibuprofen: May inhibit prostaglandin synthesis affecting ovulation, potentially delaying or impairing fertility. Pseudoephedrine: No direct fertility data; vasoconstrictive effects could theoretically affect uterine blood flow, but evidence is lacking. |
| Food/Dietary | Take with food or milk to minimize GI upset. Avoid alcohol as it may increase risk of GI bleeding. No specific food-drug interactions. |
| Clinical Pearls | Combination of ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen may increase blood pressure, counteracting pseudoephedrine's vasoconstriction; monitor in hypertensive patients. Avoid in patients with severe CAD, uncontrolled HTN, or within 2 weeks of MAOI use. |
| Patient Advice | Do not take with other NSAIDs or cold/flu products to avoid overdose. · Pseudoephedrine may cause insomnia; take last dose at least 4-6 hours before bedtime. · Ibuprofen can cause GI bleeding; take with food or milk to reduce risk. · Stop use and consult doctor if symptoms persist >7 days or if fever lasts >3 days. · Avoid alcohol while taking this medication. |